Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Prophylactic Tyrosine Kinase Inhibitor Therapy Post-transplants on Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia Undergoing Allo-HSCT With Minimal Residual Disease Positive Pre-transplants

NCT03624530 is registered in ClinicalTrials.gov with Nanfang Hospital, Southern Medical University as lead sponsor.

NCT NCT03624530
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03624530 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Prophylactic Tyrosine Kinase Inhibitor Therapy Post-transplants on Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia Undergoing Allo-HSCT With Minimal Residual Disease Positive Pre-transplants
Lead sponsor
Nanfang Hospital, Southern Medical University
Phase
Phase 2/3
Overall status
Unknown status
Start date
August 31, 2018
Completion date
July 31, 2022
Enrollment
82 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

allogeneic hematopoietic stem cell transplantation, minimal residual disease, philadelphia chromosome positive acute lymphocytic leukemia, tyrosine kinase inhibitor